- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02100540
A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women (RDC)
A Randomized, Placebo-Controlled, Double-Blind, Dose-Response, Phase 2, -Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Changhua, Taiwan, 135
- Changhua Christian Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Menopausal (postmenopausal or perimenopausal) adult women who are suffering from vasomotor symptom or women who are suffering from drug (tamoxifen or aromatase inhibitors) induced vasomotor symptoms. Women have received postsurgical bilateral oophorectomy with or without hysterectomy will be eligible for the study;
- Women who are on tamoxifen or aromatase inhibitors, it has to be for at least 8 weeks at stable dosing and will maintain at the same treatment regimen during the study;
- Menopausal (postmenopausal or perimenopausal) adult women and drug (tamoxifen or aromatase inhibitors) induced vasomotor symptoms must average 3 or more moderate to severe hot flashes per day or 25 per week. Both based upon data obtained from a completed VMS episode event log for a 1 week period prior to randomization where moderate is defined as a sensation of heat with sweating, able to continue activity, and severe is defined as a sensation of heat with sweating, causing cessation of activity. Awake at night due to sweats will be recorded separately and will be considered as severe;
- Ability to understand and follow the instructions of the investigator, including completion of the VMS episode event logs (patient diary) as described in the protocol;
- Able and willing to provide written informed consent;
- Study participants should not be taking estrogen or a SERM alone or estrogen/progestin containing drug products. The following washout periods are recommended before baseline assessments are made for subjects previously on estrogen or a SERM alone or estrogen/progestin containing products:
- 1 week for prior vaginal hormonal products (rings, creams, gels);
- ≥ 4 weeks for prior transdermal estrogen alone or estrogen/progestin products;
- ≥ 8 weeks for prior oral estrogen, SERM and/or progestin therapy;
- ≥ 8 weeks for prior intrauterine progestin therapy;
- ≥ 3 months for prior progestin implants and estrogen alone injectable drug therapy;
- ≥ 6 months for prior estrogen pellet therapy or progestin injectable drug therapy.
Exclusion Criteria:
- Hypertension with uncontrolled blood pressure (Systolic blood pressure > 150 mmHg, diastolic blood pressure > 90 mmHg) Subjects with mild to moderate hypertension who are controlled on a stable antihypertension regimen may be enrolled if they meet the other inclusion/exclusion criteria;
- Use of SSRI and/or SNRI. Prior usage of herbal or dietary supplements, including black cohosh, soy, phytoestrogens will be eligible if subject agrees to cease taking above agents during the study;
- Subjects taking or having taken any other experimental drugs, or participating in or having participated in other clinical studies in the 30 days prior to this clinical trial;
- Subjects having a known history of allergic reaction, hypersensitivity or clinically significant intolerance to ingredients of the study drug;
- Subject has a history or suspicion of cancer with exception of breast cancer;
- Subjects with a current drug or alcohol abuse problem as judged by the investigator;
- Subjects have clinical significant conditional, such as acute myocardial infarction or stroke with 6 months of randomization;
- Subjects have suicidal tendency;
- Subjects who are considered unreliable as to medication compliance or adherence to scheduled appointments or for other reasons are felt to be inappropriate for inclusion in the study as determined by the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: I placebo capsule
|
I placebo capsule
Other Names:
|
Experimental: II RDC 0.3mg capsule
|
II RDC 0.3mg capsule
Other Names:
|
Experimental: III RDC 0.6mg capsule
|
III RDC 0.6mg capsule
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change in frequency of moderate to severe vasomotor symptoms
Time Frame: baseline to weeks 4 and 12
|
baseline to weeks 4 and 12
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- YSP-RCN3028-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hot Flashes
-
Mitsubishi Tanabe Pharma America Inc.CompletedMenopause Hot FlashesUnited States
-
University of California, San FranciscoCompleted
-
University of California, San FranciscoCompleted
-
AmgenCompleted
-
Alison Huang, MDNational Institute on Aging (NIA)Completed
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedTreatment of Menopausal Hot FlashesUnited States
-
Donesta BioscienceSynteractHCRCompleted
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)CompletedHot Flashes | Hot FlushesUnited States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedFever, Sweats, and Hot FlashesUnited States
-
University of PennsylvaniaForest LaboratoriesCompleted
Clinical Trials on I placebo capsule
-
Quan JiangUnknown
-
China National Center for Cardiovascular DiseasesFuwai Hospital, Chinese Academy of Medial Sciences, Shenzhen, ShenzhenRecruitingHypertension | Diabetes | HypercholesterolemiaChina
-
Chipscreen Biosciences, Ltd.Not yet recruiting
-
Burapha UniversityCompletedAsparagus Capsule ConsumptionThailand
-
GlaxoSmithKlineCompletedAutoimmune DiseasesUnited Kingdom
-
Zydus Lifesciences LimitedCompleted
-
LEO PharmaCompletedHealthy VolunteersUnited Kingdom
-
Jaseng Medical FoundationNutribiotech Co., Ltd.; NeonutraCompleted
-
NewChapter, Inc.Procter and GambleCompletedKnee Discomfort | Pain Physical ActivityUnited States
-
Chipscreen Biosciences, Ltd.Completed